NCT05901883View on ClinicalTrials.gov

First-in-human, Single Ascending Dose Study of CEL383 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

January 17, 2024

Study Completion Date

January 17, 2024

Conditions
Healthy
Interventions
DRUG

CEL383

Subjects will receive CEL383

DRUG

Placebo

Subjects will receive placebo

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors
All Listed Sponsors
lead

Celsius Therapeutics, Inc.

INDUSTRY